Search
Chairs and Members
Chair:
Francesco Buccisano, Department of Biomedicine and Prevention, Tor Vergata University of Rome, Italy (2021-2024)
Co-Chair:
Sylvie Freeman, Clinical Immunology Service, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK (2021-2024)
SWG Executive Board members and terms:
Torsten Haferlach, MLL Munich Leukemia Laboratory, Munich, Germany…
The European Hematology Association (EHA) Announces a New Era of Partnership with Interplan as its New Core PCO
The European Hematology Association (EHA) is delighted to announce to the conference and meeting community the outcome of its Core PCO Invitation To Tender (ITT).
Read moreThe European Hematology Association (EHA) announces an Invitation to Tender (ITT) for PCO services for the EHA Annual Congress
The European Hematology Association (EHA) is pleased to inform the conference and meeting community that it will release an Invitation To Tender (ITT) for the appointment of a Professional Conference Organizer (PCO) for the EHA Congress in 2023.
Read moreEU health policy: limited scope, high ambition
Over the past decades, the European Union (EU) has become more involved in public health policy. A recent study showed that a majority of policymakers even identifies EU health policy as a priority for 2020-20241.
Read moreOpen Access: the ‘Plan S’
Research and academic groundwork funded with public means should be free and open to everyone. That is the principle behind Open Access that was formulated in 2003 in the Berlin Declaration.
EU Elections and Health Policy
HemAffairs Article #1 – June 2019
2019 will see significant changes within the European institutions.
Mission ‘Gene Therapy’ for Horizon Europe
Mission ‘Gene Therapy’ for Horizon Europe
Advanced therapies, such as gene therapy, hold promise for treating a wide range of chronic diseases and improving patients’ quality of life.
Uptake of CAR T cell therapy in Europe
Gene (editing) therapy continues to break ground in hematology, showing promising results in tackling severe blood cancers. Yet, its uptake in the European Union is slow, with few patients benefiting from it so far.
Read more